ORX Share Price Performance
SEK 0
-23.60 (-100.00%)
Price SEK 0
Fair ValueSEK 29.00
Share Pricen/a
Orexo AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
ORX Community Narratives
AN
Fair Value
·Fair Value SEK 29 54.2% undervalued intrinsic discount
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Orexo
54.2% undervalued intrinsic discount
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
View narrativeAN
Updated 13 Jun
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ORX: Overdose Reversal Pipeline Progress Will Support Future Upside
Fair Value: SEK 29 54.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Orexo AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 22, 2026
- -12.11
- 37.95%
- -2,548.19%
- 0%
About ORX
- Founded
- 1994
- Employees
- 61
- CEO
- WebsiteView website
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
